Get the Stockscreener App
6.71
2.33%
-0.16
After Hours:
6.67
-0.04
-0.60%
Day One Biopharmaceuticals Inc stock is traded at $6.71, with a volume of 1.12M.
It is down -2.33% in the last 24 hours and up +3.23% over the past month.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.
See More
Previous Close:
$6.87
Open:
$6.83
24h Volume:
1.12M
Relative Volume:
0.81
Market Cap:
$680.14M
Revenue:
-
Net Income/Loss:
$-167.48M
P/E Ratio:
-3.441
EPS:
-1.95
Net Cash Flow:
$-197.47M
1W Performance:
-6.93%
1M Performance:
+3.23%
6M Performance:
-45.76%
1Y Performance:
-53.11%
1-Day Range:
$6.60
$6.87
1-Week Range:
$6.60
$7.40
52-Week Range:
$6.08
$16.76
Day One Biopharmaceuticals Inc Stock (DAWN) Company Profile
Name
Day One Biopharmaceuticals Inc
Sector
Industry
Phone
650 484-0899
Address
2000 SIERRA POINT PARKWAY, SUITE 501, BRISBANE
Compare DAWN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DAWN
Day One Biopharmaceuticals Inc
|
6.71 | 696.36M | 0 | -167.48M | -197.47M | -1.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Day One Biopharmaceuticals Inc Stock (DAWN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-09-24 | Reiterated | Needham | Buy |
| Aug-01-24 | Upgrade | BofA Securities | Underperform → Buy |
| Apr-24-24 | Reiterated | Needham | Buy |
| Apr-25-23 | Downgrade | BofA Securities | Buy → Underperform |
| Feb-08-23 | Initiated | CapitalOne | Overweight |
| Feb-03-23 | Initiated | Oppenheimer | Perform |
| Dec-15-22 | Initiated | H.C. Wainwright | Buy |
| Dec-14-22 | Initiated | Needham | Buy |
| Dec-05-22 | Initiated | Goldman | Buy |
| Dec-01-22 | Initiated | BofA Securities | Buy |
View All
Day One Biopharmaceuticals Inc Stock (DAWN) Latest News
Can a trend reversal in Day One Biopharmaceuticals Inc. lead to recoveryYield Curve Outlook and Long-Term Implication Summary - Newser
What makes Day One Biopharmaceuticals Inc. stock price move sharplyChart Pattern Recommendation For Smart Trading - jammulinksnews.com
Day One Biopharmaceuticals Inc. stock chart pattern explainedRisk/Reward Optimization Entry Point Analysis - Newser
What is the risk reward ratio of investing in Day One Biopharmaceuticals Inc. stockPre Market Review For Consistent Profits - jammulinksnews.com
Published on: 2025-07-30 22:40:17 - Newser
Can Day One Biopharmaceuticals Inc. recover in the next quarterWeekly Stock Opportunity Radar Scanner Activated - metal.it
How Day One Biopharmaceuticals Inc. stock performs during market volatilityNeural Model for Stock Price Movement - Newser
Published on: 2025-07-30 04:25:27 - Newser
Trapped Investors in Day One Biopharmaceuticals Inc. Await Breakout SignalMulti-Bagger Potential Stock Forecast Tools Released - beatles.ru
How institutional ownership impacts Day One Biopharmaceuticals Inc. stockFree Short Term Buy Zone Stock Alerts - Newser
Comparing Day One Biopharmaceuticals Inc. in custom built stock radarsAsset Growth Pattern and Return Summary - Newser
Cwm LLC Acquires 21,639 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
Published on: 2025-07-29 09:05:06 - metal.it
Why Day One Biopharmaceuticals Inc. stock attracts strong analyst attentionStrategy Builder for Growth Focused Traders - Newser
Is There Enough Volume to Lift Day One Biopharmaceuticals Inc.Fast Gaining Stock Screener Reports Released - metal.it
Published on: 2025-07-28 22:51:58 - metal.it
What is the dividend policy of Day One Biopharmaceuticals Inc. stockBoost your returns with professional guidance - jammulinksnews.com
How strong is Day One Biopharmaceuticals Inc. company’s balance sheetFree Stock Market Real-Time Monitoring - jammulinksnews.com
How many analysts rate Day One Biopharmaceuticals Inc. as a “Buy”Get alerts on high-potential stock breakouts - jammulinksnews.com
Will Day One Biopharmaceuticals Inc. see short term momentumFree High Return Stock Focus With Safety - Newser
How volatile is Day One Biopharmaceuticals Inc. stock compared to the marketUnlock powerful market trend analysis - jammulinksnews.com
What catalysts could drive Day One Biopharmaceuticals Inc. stock higher in 2025Capital growth strategies that work - jammulinksnews.com
Is it the right time to buy Day One Biopharmaceuticals Inc. stockMaximize gains with strategic stock entries - jammulinksnews.com
Buy Signal for Day One Biopharmaceuticals Inc. Stock Key Technical Indicators to WatchFree Step-by-Step Investment Guide - Newser
What analysts say about Day One Biopharmaceuticals Inc. stockBreakthrough capital growth - PrintWeekIndia
What drives Day One Biopharmaceuticals Inc. stock priceHigh-yield portfolio picks - PrintWeekIndia
Will Day One Biopharmaceuticals Inc. stock benefit from interest rate changesExponentially increasing returns - jammulinksnews.com
Exploring High Growth Tech Stocks in the US This July 2025 - simplywall.st
Is Day One Biopharmaceuticals Inc. a good long term investmentConsistent double returns - Autocar Professional
When is the best time to buy Day One Biopharmaceuticals Inc. stockFree Bull & Bear Market Updates - jammulinksnews.com
Will Day One Biopharmaceuticals Inc. stock benefit from AI tech trendsMarket-beating performance - jammulinksnews.com
Wall Street Analysts Believe Day One Biopharmaceuticals (DAWN) Could Rally 303.46%: Here's is How to Trade - Zacks Investment Research
Arizona State Retirement System Reduces Stake in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
BlackRock, Inc. Reduces Stake in Day One Biopharmaceuticals Inc - GuruFocus
Day One Biopharmaceuticals Inc. Stock Analysis and ForecastBreakthrough profit margins - jammulinksnews.com
Day One Biopharmaceuticals Inc Stock (DAWN) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):